You are here: Industry Insights > antibody

News List

New Treatment Greatly Boosts Survival for Kids With Aggressive Brain Cancer Drugs
December 13, 2021
Children with the rare cancer neuroblastoma often succumb to the disease despite aggressive treatment. But researchers have found that adding an experimental antibody to that treatment, right off the bat, may improve their outlook.
New Asthma Drug, Dupilumab (Dupixent) Helps Kids, But Price Tag Is High Drugs
December 10, 2021
Children with hard-to-control asthma may get relief from adding an injectable antibody drug to their standard treatment, a clinical trial has found.
FDA OKs Antibody Cocktail to Help Immune-Compromised Fend Off COVID Drugs
December 10, 2021
The U.S. Food and Drug Administration on Wednesday granted emergency approval of a new antibody cocktail to prevent COVID infection in people who have weakened immune systems or who can't tolerate COVID vaccines.
Twist Bioscience agrees to acquire Abveris for $190m Pharmaceutical-Technology
November 24, 2021
Twist Bioscience has signed a definitive agreement to acquire in vivo antibody discovery services firm Abveris for up to $190m to boost its biopharma expertise.
Booster Shots Prompt Stronger, Longer Protection Than Original Shots: Study Drugs
November 23, 2021
COVID-19 booster shots trigger much stronger and longer protection than full vaccination with two doses of the Pfizer or Moderna vaccines, according to a small study.
New Analyses of Two AZD7442 Covid-19 Trials Confirm Robust Efficacy and Long-Term Prevention in High-Risk Populations AmericanPharmaceuticalReview
November 22, 2021
New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics ExpressPharma
November 19, 2021
Twist Bioscience Corporation has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize an antibody...
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust efficacy and long-term prevention ExpressPharma
November 19, 2021
AstraZeneca yesterday said that new data from the AZD7442 COVID-19 Provent prevention and Tackle outpatient treatment phase-III trials showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
Twist Bioscience launches new company for Covid-19 antibody treatments Pharmaceutical-Technology
November 17, 2021
Twist Bioscience has announced the formation of an independently operated biotechnology company, Revelar Biotherapeutics, which will develop and market new Covid-19 and other antibody therapies...
Validation Study Showcases Success of LSBD's Rapid SARS-CoV-2 Antibody Test prnasia
November 16, 2021
The iQ Group Global Ltd (iQG Ltd) (NSX:IQG) on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), has announced the successful completion of a clinical validation study showcasing the efficacy...